Furthermore, the expression of GLI1 and GLI2 suggestive of pathway activation in clinical specimens is associated with chemotherapeutic resistance and inferior survival rates, providing additional evidence that HH signaling is clinically relevant in patients with AML and myelodysplastic syndrome (MDS) [35,36,37,38]. The gene discussed is GLI2; the disease is acute myeloid leukemia.